Acute esophageal toxicity in non-small cell lung cancer patients after high dose conformal radiotherapy

被引:150
作者
Belderbos, J [1 ]
Heemsbergen, W [1 ]
Hoogeman, M [1 ]
Pengel, K [1 ]
Rossi, M [1 ]
Lebesque, J [1 ]
机构
[1] Antoni Van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Radiat Oncol, NL-1066 CX Amsterdam, Netherlands
关键词
lung cancer; conformal radiotherapy; acute esophageal toxicity; equivalent uniform dose; dose-volume histogram;
D O I
10.1016/j.radonc.2005.03.021
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and purpose: To correlate acute esophageal toxicity with dosimetric and clinical parameters for non-small cell lung cancer (NSCLC) patients treated with radiotherapy (RT) alone or with chemo-radiotherapy (CRT). Patients and methods: We analyzed the data of 156 patients with medically inoperable or locally advanced NSCLC. Seventy-four patients were irradiated with high dose RT only, 45 patients with sequential CRT (Gemicitabine/Cisplatin) and 37 patients with concurrent CRT (Cisplatin daily 6 mg/m(2)). The radiation dose delivered ranged from 49.5 to 94.5 Gy (2.25-2.75 Gy per fraction) with an overall treatment time of 5-6 weeks. For all patients the maximal acute esophageal toxicity (RTOG/EORTC criteria) was scored and related to dose-volume parameters, as well as to clinical and treatment-related parameters. All parameters were tested univariable and multivariable in a binary logistic regression model. The toxicity data of a homogeneous subgroup was fitted to the Lyman-Kutcher-Burman model. Results: Grade 2 acute esophageal toxicity or higher occurred in 27% (n = 42) of the patient population of which nine patients developed grade 3 toxicity and one patient grade 4. All 10 patients with grade >= 3 esophageal toxicity received concurrent CRT. At multivariable analysis, the most significant clinical parameter to predict acute esophageal toxicity was the concurrent use of CRT. The most significant dosimetric parameter was the esophagus volume that received at least 35 Gy. The data of the patients who did not receive concurrent CRT were well described by the Lyman-Kutcher-Burman normal tissue complication probability model. The optimal fit of the data of non-concurrent treated patients to this model was obtained using the following values for the parameters: TD50 = 47 Gy (41-60 Gy), n = 0.69 (0.18-6.3) and m = 0.36 (0.25-0.55) where the numbers between brackets denote the 95% confidence interval. Acute esophageal toxicity was not significantly increased for patients treated with sequential CRT. Conclusion: Both concurrent CRT and the volume that receives at least 35 Gy were predictors of acute esophageal toxicity. (c) 2005 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:157 / 164
页数:8
相关论文
共 26 条
[1]  
[Anonymous], 1993, ICRU report 50, DOI 10.1118/1.597396
[2]   First results of a phase I/II dose escalation trial in non-small cell lung cancer using three-dimensional conformal radiotherapy [J].
Belderbos, JSA ;
De Jaeger, K ;
Heemsbergen, WD ;
Seppenwoolde, Y ;
Baas, P ;
Boersma, LJ ;
Lebesque, JV .
RADIOTHERAPY AND ONCOLOGY, 2003, 66 (02) :113-120
[3]   Dosimetric correlates for acute esophagitis in patients treated with radiotherapy for lung carcinoma [J].
Bradley, J ;
Deasy, JO ;
Bentzen, S ;
El Naqa, I .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 58 (04) :1106-1113
[4]   Response, toxicity, failure patterns, and survival in five radiation therapy oncology group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung [J].
Byhardt, RW ;
Scott, C ;
Sause, WT ;
Emami, B ;
Komaki, R ;
Fisher, B ;
Lee, JS ;
Lawton, C .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1998, 42 (03) :469-478
[5]  
Choy H, 1999, SEMIN RADIAT ONCOL, V9, P90
[6]   Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer [J].
Furuse, K ;
Fukuoka, M ;
Kawahara, M ;
Nishikawa, H ;
Takada, Y ;
Kudoh, S ;
Katagami, N ;
Ariyoshi, Y .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2692-2699
[7]   Radiation pneumonitis after breast cancer irradiation:: Analysis of the complication probability using the relative seriality model [J].
Gagliardi, G ;
Bjöhle, J ;
Lax, I ;
Ottolenghi, A ;
Eriksson, F ;
Liedberg, A ;
Lind, P ;
Rutqvist, LE .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 46 (02) :373-381
[8]   Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: Update of a phase I trial [J].
Hayman, JA ;
Martel, MK ;
Ten Haken, RK ;
Normolle, DP ;
Todd, RF ;
Littles, JF ;
Sullivan, MA ;
Possert, PW ;
Turrisi, AT ;
Lichter, AS .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (01) :127-136
[9]   Dosimetric predictors of radiation esophagitis in patients treated for non-small-cell lung cancer with carboplatin/paclitaxel/radiotherapy [J].
Hirota, S ;
Tsujino, K ;
Endo, M ;
Kotani, Y ;
Satouchi, M ;
Kado, T ;
Hishikawa, Y ;
Obayashi, K ;
Takada, Y ;
Kono, M ;
Abe, M .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001, 51 (02) :291-295
[10]   Quantification of local rectal wall displacements by virtual rectum unfolding [J].
Hoogeman, MS ;
van Herk, M ;
de Bois, J ;
Muller-Timmermans, P ;
Koper, PCM ;
Lebesque, JV .
RADIOTHERAPY AND ONCOLOGY, 2004, 70 (01) :21-30